Tenderwize
Zurück zur Suche

Pharmaceuticals with active substance Erythropoietin (ATC: B03XA01 - strength over 10,000 IU per dosage unit)

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline Aug 30, 2026 · 5 days left·Open·Supplies
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Erythropoietin (ATC: B03XA01 - in der Wirkstärke über 10.000 IE je Dosiereinheit)

70/100

Opportunity Score

PromisingLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

70 / 100

Komplexität

20 / 100

Risikofaktoren

AOK may terminate agreements early if exclusive contracts are tendered for the same active substance during the contrac...

No guaranteed volume; actual sales depend on prescription behavior and number of participants.

Submission deadline in 5 days

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Strong opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Supply of Erythropoietin pharmaceuticals (ATC B03XA01, >10,000 IU per dose unit) under non-exclusive discount agreements.
  • Open-house model allowing any eligible pharmaceutical company to participate at any time.
Vollständige Zusammenfassung anzeigen

This is an open-house model for non-exclusive discount agreements on Erythropoietin pharmaceuticals (strength >10,000 IU per dose unit) with AOK Sachsen-Anhalt. Any eligible pharmaceutical company can conclude a contract at any time under uniform conditions. The contract runs from earliest 01.11.2024 to 31.10.2026 (max 24 months). No estimated value or guaranteed volume is provided. The tender is not a public procurement under GWB but published for transparency.

Risiken

AOK may terminate agreements early if exclusive contracts are tendered for the same active substance during the contrac...

No guaranteed volume; actual sales depend on prescription behavior and number of participants.

Submission deadline in 5 days

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Must be a pharmaceutical company or consortium of pharmaceutical companies.

Administrative

  • Must request and submit completed participation documents and signed contract.
  • Must meet uniform contract conditions (not specified in detail).

Zuschlagskriterien

Lot 1

No competitive award; contract available to all eligible participants.

Auftraggeber

Ort

Magdeburg, DEU

Auftraggeberprofil

Profil öffnen

Kennung

DE258393558

Tätigkeit

Health

Lose (1)

LOT-0001

Pharmaceuticals with active substance Erythropoietin (ATC: B03XA01 - strength over 10,000 IU per dosage unit)

Conclusion of non-exclusive discount agreements for finished medicinal products containing Erythropoietin (ATC: B03XA01, strength >10,000 IU) under an open-house model. Any eligible pharmaceutical company can join at any time with standard contract terms. No exclusivity.

SuppliesEU fundedElectronic submission

Ort

DEE03, Germany

Dauer

2 YEAR

Kategorie

Pharmaceutical products

Zuschlagskriterien

No competitive award; contract available to all eligible participants.

Frist

Deadline Aug 30, 2026

Vergabedetails

Veröffentlichungsdatum
19 Sep 2024
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
567828-2024

Dokumente (1)

Ähnliche Ausschreibungen